Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
The company should maintain its lead in this growing area. Novo Nordisk (NVO -0.88%) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal …